Clinical Trial Update: Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluating the safety and efficacy of AVP-923 for emotional lability in patients with amyotrophic lateral sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AVP-923

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Amyotrophic Lateral Sclerosis | Phase 3 | Status: COMPLETED